Most lab tests that look for a specific molecule in a drop of fluid rely on the same trick: catch the target between two binders, like a sandwich. One binder grabs the target so it can be held in place; the other carries a tag that produces a signal you can measure. The catch is everything around that elegant idea. You need to separate the sandwiches that formed from leftover reagent that did not, read a faint signal reliably, and ideally do it outside a central lab, fast, with a device a non-specialist can operate. A newly published Kephera Diagnostics application, surfaced in this week's patent pub drop, folds that whole workflow into a single handheld-scale instrument and a matching reagent kit. The hero of the filing is US20260177549A1, titled "Methods, Diagnostic Instruments, and Kits for Detecting Diseases," a pending application published June 25, 2026 and classified under CPC G01N 33/54388, an immunoassay class for analytical chemistry.

The technical heart of the device is how it does the separation. In a classic immunoassay you immobilize one binder on a plate or a membrane and physically wash everything else away. This application replaces the wash-and-immobilize step with magnetism inside a capillary. The disclosed method contacts the sample with a first binding molecule that is bound to a detectable label, and a second binding molecule that is bound to a magnetic particle. If the target analyte is present, it ends up bridged between the two binders, so a single complex now carries both a glowing tag and a magnetic handle. The sample flows into a slim capillary vessel with an entry port at one end and an exit port toward the other, and a magnet is applied to a portion of that capillary. Anything wearing the magnetic handle, meaning the captured target, gets pulled to the magnetic zone and held there; everything unbound keeps moving toward the exit. The instrument then looks at just that zone for a signal.

Provided herein are methods, diagnostic instruments, and kits for detecting the presence or absence of an analyte associated with a disease in a subject.— Methods, Diagnostic Instruments, and Kits for Detecting Diseases, US20260177549A1

How does a magnet inside a capillary replace a wash step?

Think of it like using a magnet to pull iron filings out of a tray of sand instead of trying to sieve them. The application's premise is that you do not need to immobilize a binder on a surface at all if one of your binders carries its own magnet. The disclosed magnetic particle is a magnetic bead, and the magnetic field is generated either by a magnet or an electromagnetic device, with the magnet option naming rare-earth materials such as neodymium or samarium-cobalt. The filing describes concentrating that field on a portion of the capillary at or around its middle, which means the captured target piles up exactly where the instrument is set to look. The claims spell out the consequence directly: the magnetic field separates analyte bound to both binding molecules from analyte that is not bound. So the magnet does the job a wash buffer and a coated surface would do in a plate assay, but in flowing fluid, in place, in seconds.

The signal side is the other half of the engineering. The detectable label in the preferred embodiment is europium, a lanthanide whose luminescence is a workhorse in sensitive assays because it emits in a narrow band and lingers slightly after excitation, which lets a reader distinguish the real signal from background flash. The disclosure also keeps the door open to colorimetric and radiometric labels, and lists enzyme substrates such as TMB, OPD, ABTS, and luminol for cases where the readout comes from an enzyme reaction rather than a direct glow. Notably, the application puts a number on speed: it describes detecting the label in a window on the order of tens of seconds after the sample enters the capillary, with nested ranges narrowing toward roughly fifty to seventy seconds. That timing target is what marks this as a point-of-care design rather than a send-it-to-the-lab one.

One filing is a method, an instrument, and a kit at once

What makes the application read like a full product disclosure rather than a single idea is that it describes three layers of the same system. There is the method, summarized above. There is the diagnostic instrument, described as a device adapted to receive the capillary vessel, with a means to apply the magnetic field to a portion of the capillary between the entry and exit ports and a means to detect the signal there. The instrument embodiments add an excitation source aimed at the middle of the capillary to light up the europium tag, a capillary pad in fluid communication with the exit port to wick spent fluid, and an option to induce flow by capillary action or a peristaltic pump. The disclosure is explicit that the instrument is adapted to form a substantially light-tight interior space, which is exactly what a luminescence reader needs so stray room light does not drown the signal.

The third layer is the kit, and it is described in several configurations: at minimum a first reagent with the label-bearing binder and a second reagent with the magnetic-particle-bearing binder, optionally adding a capillary vessel, a capillary pad, a wash buffer, and instructions for use. The application also describes a housing assembly with a top portion holding one or more cameras and excitation sources and a bottom portion holding the magnet, with a toggleable switch that powers the optics and starts fluid flow, and a top-to-bottom seal that creates the light-tight enclosure. In plain terms, the filing covers the consumable you load, the reader you load it into, and the box that holds the optics and magnet in the dark. The listed sample types are the kind a point-of-care device would actually see, including saliva, oral fluid, tears, urine, and nasal or nasopharyngeal fluid, and the analytes are described at the device level as antibodies, antigens, proteins, peptides, or oligonucleotides. The infectious-disease markers named in the abstract, associated with Lyme disease, SARS-CoV-2, and HIV, appear strictly as detection targets the assay is configured to recognize; the disclosure is about the device and the binding chemistry, not about treatment.

Where it sits in the diagnostics field

Magnetic-bead capture, sandwich immunoassays, and time-resolved europium luminescence are each well-established techniques on their own. What this application discloses is a specific integration of them: bead-based capture and a glowing tag combined inside a flowing capillary, with a concentrated magnetic field doing the separation in place and a light-tight reader over the capture zone. That combination aims the design at fast, decentralized testing. This week's pub drop is thick with diagnostic-instrument engineering of other flavors. US20260177523A1 describes a graphene-based field-effect-transistor sensor array that reads nucleic-acid hybridization electronically rather than optically. US20260174336A1 describes an intraoperative probe fusing Raman spectroscopy and shear-wave elastography. US20260174571A1 describes a diagnostic metamaterial cardiovascular stent that signals through contact electrification, and US20260176695A1 describes a method and kit for a transcriptomic-signature diagnostic tool. Optical, electronic, spectroscopic, mechanical, molecular: the same week shows the breadth of detection-instrument engineering.

One caveat is load-bearing. This is a published application, not a granted patent. It describes what Kephera Diagnostics disclosed and sought to protect, not a cleared product or an enforceable right, and the claims that eventually issue may be narrower than the abstract reads. But as assay engineering written down, the filing is self-contained: it takes the familiar sandwich-immunoassay idea, swaps a coated plate and a wash step for a magnet and a capillary, reads the result with a europium tag in a light-tight box, and packages it as an instrument plus a consumable kit aimed at an answer in under a couple of minutes.